STOCK TITAN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Summary
Innate Pharma has announced the initiation of the Phase 2 MATISSE trial, evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi and chemotherapy in early stage lung cancer. The primary objectives of the study are to assess antitumor activity and safety. The trial is conducted in collaboration with AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
clinical trial
-
Rhea-AI Summary
Innate Pharma has announced the initiation of the Phase 2 MATISSE trial, evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi and chemotherapy in early stage lung cancer. The primary objectives of the study are to assess antitumor activity and safety. The trial is conducted in collaboration with AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
partnership
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

AZN Stock Data

211.63B
1.54B
0.01%
16.79%
0.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.